Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials
about
Progestin effects on cell proliferation pathways in the postmenopausal mammary glandPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBone Metastasis from Renal Cell CarcinomaHypercalcemia of malignancy and new treatment optionsOsteochemonecrosis: an overviewWhere Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Targeting RANKL in metastasisCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone-Targeted TherapyBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Considering renal risk while managing cancer.Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab.New strategies in the treatment of multiple myeloma.Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.New prognostic factors and scoring system for patients with skeletal metastasis.Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasisPrevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesMeasurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesSpontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse modelOsteonecrosis of the jaw (ONJ): diagnosis and management in 2015.Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United StatesPhysician preferences for bone metastasis drug therapy in Canada.Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerSinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunitiesJBO-Launched and flying ahead.Bone metastases: Are we failing our patients?Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countriesPain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
P2860
Q21092903-E7937BFB-2978-417F-8010-8CF4B797879EQ26746212-EF0E7C46-A7EF-47AD-8BC4-1B63A3C79066Q26747493-112DAF1D-1906-41E4-B2AA-05F2EDC7C6F7Q26775300-55C00BCB-599F-4EC6-9F30-3646D15649D0Q26827072-97C282FE-8A91-4EC7-95BE-1C1EE179BFBDQ26849473-8A31173A-3073-4D98-B4D3-144E54EA8006Q26849690-393588DD-4D4F-4BAE-B4D2-7B4D19D0D419Q27302940-35B5B0BE-3D50-4692-AB90-4B98C4511381Q28068956-8F053C66-EFD3-4422-86F1-8AD68D1E0AB6Q28076646-366C14B2-8E97-40FD-A574-CB8C903D5FBAQ28081294-490B6463-47C0-4668-BD7B-35AA056A42F1Q28087676-66ADCD8F-FFE4-42E9-AF18-BC5A8E8F6DDEQ30234338-B8AD6273-E096-4C30-B7A3-19EE08EFB336Q30239854-716025F2-EAED-4FEA-983C-7BC254428CECQ30367068-EFFFC2BE-5D69-4F4D-83EC-076B3A126252Q30409623-6DD407E0-245A-416C-AD1D-EEAE2F994F35Q30684593-B0AB4FE5-98A3-4AEF-A8E0-6BABBFF53A5EQ30852837-3BF31CAA-A6DE-4A20-8320-97C4A8DC9B7BQ33574428-D0A16D68-2C2E-4EE6-AAAA-EE89601B8427Q33620502-7CFADF3F-A8F4-43CF-ADAC-D7FF5FFB4C85Q33697117-587DFDD2-0C4E-4395-B656-00E09F1939CEQ33958520-E26766C1-0205-4A30-BF84-227F948D57FCQ34718400-CCCDFF8B-571C-4304-9DFC-242EFD0BDA2BQ34998576-29370C7F-E61E-4C70-A708-4C460159F718Q35125558-086F181D-EF2F-4FCA-AD81-D58AE27357D4Q35345620-72CFF394-9E75-47BE-8E6D-77C5493F03C6Q35667318-AEA3120F-7AD1-4990-B59A-EE322FF3B47FQ35749531-8ECB5C52-FC84-4DB5-B760-47E2763C1B85Q35750641-673F12BF-030B-43BA-8215-4FCEC8C717FDQ35764778-B3D9D751-5C82-433C-A9DE-F5A41E70EA79Q35818022-DECD6F42-4F7E-48A9-9689-9E578921DAD3Q35887353-FDA8DAFC-242D-4931-8468-F31C1759E9C4Q36169862-6215E12D-ED59-42A1-A772-63345C8E5569Q36345986-E2F43722-0213-4B6C-8393-D32DF239CA53Q36433392-8997A70E-79A9-4D91-80A6-B1B2A2F4B714Q36447553-1E3ACCE2-04C8-4B42-B24D-908FCE420530Q36491450-BFE50A0F-FAAA-47F4-B4B0-CC5E31B2E79FQ36492217-57CABF89-B664-4913-A461-9B0162C5E3F0Q36492222-F5C35DF5-4FE5-4E13-B5FF-B2CA60A9231DQ36510928-68A29D5B-4FD4-407D-A9F7-6F1CC48D06D3
P2860
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@ast
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@en
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@nl
type
label
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@ast
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@en
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@nl
prefLabel
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@ast
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@en
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@nl
P2093
P3181
P1476
Superiority of denosumab to zo ...... al, randomised, phase 3 trials
@en
P2093
Alison T Stopeck
Allan Lipton
Boris Bilynskyy
Chunlei Ke
David H Henry
Denise A Yardley
Gary E Richardson
Janet E Brown
P304
P3181
P356
10.1016/J.EJCA.2012.08.002
P407
P50
P577
2012-11-01T00:00:00Z